Bill Maughan
Stock Analyst at Clear Street
(1.69)
# 4,104
Out of 5,182 analysts
23
Total ratings
37.5%
Success rate
-9.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bill Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Buy | $100 → $130 | $87.16 | +49.15% | 2 | Mar 10, 2026 | |
| OCUL Ocular Therapeutix | Maintains: Buy | $21 → $28 | $9.52 | +194.12% | 1 | Mar 3, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $10 → $18 | $12.84 | +40.19% | 2 | Feb 19, 2026 | |
| CRBU Caribou Biosciences | Initiates: Buy | $13 | $2.13 | +510.33% | 1 | Feb 2, 2026 | |
| CLLS Cellectis | Initiates: Buy | $9 | $4.01 | +124.44% | 1 | Dec 23, 2025 | |
| WVE Wave Life Sciences | Maintains: Buy | $22 → $47 | $6.94 | +577.23% | 2 | Dec 9, 2025 | |
| ANNX Annexon | Initiates: Buy | $17 | $6.10 | +178.69% | 1 | Dec 2, 2025 | |
| KRYS Krystal Biotech | Initiates: Buy | $190 | $272.75 | -30.34% | 1 | Jul 1, 2025 | |
| CRSP CRISPR Therapeutics AG | Downgrades: Hold | $45 | $50.99 | -11.75% | 1 | Jun 27, 2025 | |
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $2.83 | +430.04% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $9 | $1.31 | +587.02% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $63 → $67 | $28.56 | +134.59% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $91 → $106 | $48.70 | +117.66% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $24 | $2.25 | +966.67% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $4.77 | +1,157.86% | 1 | Feb 21, 2024 |
Dianthus Therapeutics
Mar 10, 2026
Maintains: Buy
Price Target: $100 → $130
Current: $87.16
Upside: +49.15%
Ocular Therapeutix
Mar 3, 2026
Maintains: Buy
Price Target: $21 → $28
Current: $9.52
Upside: +194.12%
Korro Bio
Feb 19, 2026
Upgrades: Buy
Price Target: $10 → $18
Current: $12.84
Upside: +40.19%
Caribou Biosciences
Feb 2, 2026
Initiates: Buy
Price Target: $13
Current: $2.13
Upside: +510.33%
Cellectis
Dec 23, 2025
Initiates: Buy
Price Target: $9
Current: $4.01
Upside: +124.44%
Wave Life Sciences
Dec 9, 2025
Maintains: Buy
Price Target: $22 → $47
Current: $6.94
Upside: +577.23%
Annexon
Dec 2, 2025
Initiates: Buy
Price Target: $17
Current: $6.10
Upside: +178.69%
Krystal Biotech
Jul 1, 2025
Initiates: Buy
Price Target: $190
Current: $272.75
Upside: -30.34%
CRISPR Therapeutics AG
Jun 27, 2025
Downgrades: Hold
Price Target: $45
Current: $50.99
Upside: -11.75%
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.83
Upside: +430.04%
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $1.31
Upside: +587.02%
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $28.56
Upside: +134.59%
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $48.70
Upside: +117.66%
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $2.25
Upside: +966.67%
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $4.77
Upside: +1,157.86%